Tumor Biology

, Volume 36, Issue 5, pp 3957–3967 | Cite as

Down-regulation of TIMP-1 inhibits cell migration, invasion, and metastatic colonization in lung adenocarcinoma

  • Ying-Hua Chang
  • Yi-Jen Chiu
  • Hung-Chi Cheng
  • Fang-Ju Liu
  • Wu-Wei Lai
  • Hsiao-Jen Chang
  • Pao-Chi Liao
Research Article


Tissue inhibitor metalloproteinase-1 (TIMP-1) is clinically associated with a poor prognosis for various cancers, but the roles of TIMP-1 in lung cancer metastasis are controversial. Our previous secretomic study revealed that TIMP-1 is highly abundant in high invasiveness cells of lung adenocarcinoma. In the current study, TIMP-1 abundances in primary lung adenocarcinoma tissues, as revealed by immunohistochemistry, are significantly higher in patients with lymph invasion and distant metastasis than in those without. Receiver operating characteristic curve analyses suggest 73.7 and 86.2 % accuracy to separate patients with lymph node and distant metastasis and those without, respectively. Moreover, we demonstrate that the expression level of TIMP-1 positively associates with cell mobility, invasiveness, and metastatic colonization. Most notably, the novel mechanism in which TIMP-1 facilitates metastatic colonization through the mediation of pericellular polyFN1 assembly was revealed. In summary, this study presents novel functions of TIMP-1 in promoting cancer metastasis and suggests TIMP-1 is a potential tissue biomarker for lymph invasion and distant metastasis of lung adenocarcinoma.


TIMP-1 Migration Invasion Metastatic colonization Pericellular fibronectin assembly Lung adenocarcinoma 



This study was supported by Grant MOST103-2113-M-006-003-MY3, MOST102-2325-B-006-003, MOST100-2113-M-006-002-MY3 from the National Science Council. We thank the Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital, for preparing the tissue microarray and for providing immunohistochemistry technology. Additionally, we are grateful for the assistance of Dr. Kuen-Jer Tsai and Miss Ya-Chun Hsiao for their services involving TMA image quantification using FACS-like Tissue Cytometry with HistoQuest from Optical Imaging Core Laboratory, Research Center of Clinical Medicine, National Cheng Kung University Hospital.

Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  2. 2.
    Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28:1248–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Carmichael DF, Sommer A, Thompson RC, Anderson DC, Smith CG, Welgus HG, et al. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci U S A. 1986;83:2407–11.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Docherty AJ, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 1985;318:66–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(Suppl):S42–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 1998;10:667–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee JH, Choi JW, Kim YS. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis. J Gastrointest Liver Dis. 2011;20:287–91.Google Scholar
  9. 9.
    Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer—an update. Acta Oncol. 2008;47:580–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Grunnet M, Mau-Sorensen M, Brunner N. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol. 2013;48:899–905.CrossRefPubMedGoogle Scholar
  11. 11.
    Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer. 2011;117:517–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Pesta M, Kulda V, Kucera R, Pesek M, Vrzalova J, Liska V, et al. Prognostic significance of TIMP-1 in non-small cell lung cancer. Anticancer Res. 2011;31:4031–8.PubMedGoogle Scholar
  13. 13.
    Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T, Santala M. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res. 2008;28:2715–9.PubMedGoogle Scholar
  14. 14.
    Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008;1:re6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003;278:40364–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005;65:898–906.PubMedGoogle Scholar
  18. 18.
    Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res. 2004;301:158–67.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamada E, Tobe T, Yamada H, Okamoto N, Zack DJ, Werb Z, et al. TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol. 2001;16:87–97.PubMedGoogle Scholar
  20. 20.
    John AS, Hu X, Rothman VL, Tuszynski GP. Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion. Exp Mol Pathol. 2009;87:184–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, Gerg M, et al. Tumor cell-derived TIMP-1 is necessary for maintaining metastasis-promoting met-signaling via inhibition of adam-10. Clin Exp Metastasis. 2011;28:793–802.CrossRefPubMedGoogle Scholar
  22. 22.
    Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 2007;67:8615–23.CrossRefPubMedGoogle Scholar
  23. 23.
    Jung YS, Liu XW, Chirco R, Warner RB, Fridman R, Kim HR. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One. 2012;7:e38773.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3218–29.CrossRefGoogle Scholar
  25. 25.
    Chang YH, Lee SH, Liao IC, Huang SH, Cheng HC, Liao PC. Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol Cell Proteomics. 2012;11:1320–39.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Chiu KH, Chang YH, Wu YS, Lee SH, Liao PC. Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J Proteome Res. 2011;10:1110–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Yang PC, Luh KT, Wu R, Wu CW. Characterization of the mucin differentiation in human lung adenocarcinoma cell lines. Am J Respir Cell Mol Biol. 1992;7:161–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem. 1998;273:24207–15.CrossRefPubMedGoogle Scholar
  29. 29.
    Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Taube ME, Liu XW, Fridman R, Kim HR. TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene. 2006;25:3041–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Jee BK, Park KM, Surendran S, Lee WK, Han CW, Kim YS, et al. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Biochem Biophys Res Commun. 2006;342:655–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Qiu Q, Yang M, Tsang BK, Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction. 2004;128:355–63.CrossRefPubMedGoogle Scholar
  33. 33.
    Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer. 2003;105:340–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Reed MJ, Koike T, Sadoun E, Sage EH, Puolakkainen P. Inhibition of TIMP1 enhances angiogenesis in vivo and cell migration in vitro. Microvasc Res. 2003;65:9–17.CrossRefPubMedGoogle Scholar
  35. 35.
    Shen W, Zhu J, Yu Z, Xue Q. TIMP-1 secreted by fibroblasts inhibits tumor cell invasion and metastasis in mouse melanoma. J Biomed Eng. 2009;26:610–4.Google Scholar
  36. 36.
    Yamauchi K, Ogata Y, Nagase H, Shirouzu K. Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today. 2001;31:791–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer. 1995;63:680–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Shi Y, Parhar RS, Zou M, Al-Mohanna FA, Paterson MC. Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid DNA encoding tissue inhibitor of metalloproteinases-1. Cancer Gene Ther. 2002;9:126–32.CrossRefPubMedGoogle Scholar
  39. 39.
    Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma. PLoS One. 2012;7:e46318.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endoc Relat Cancer. 2005;12:215–27.CrossRefGoogle Scholar
  41. 41.
    Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178–93.CrossRefPubMedGoogle Scholar
  42. 42.
    Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25:99–113.CrossRefPubMedGoogle Scholar
  43. 43.
    Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci. 2006;36:23–30.PubMedGoogle Scholar
  44. 44.
    Klintman M, Ornbjerg Wurtz S, Christensen IJ, Braemer Hertel P, Ferno M, Malmberg M, et al. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2010;121:365–71.CrossRefPubMedGoogle Scholar
  45. 45.
    Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics. 2003;2:164–72.CrossRefPubMedGoogle Scholar
  46. 46.
    Schrohl AS, Look MP, Meijer-van Gelder ME, Foekens JA, Brunner N. Tumor tissue levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: a retrospective study. BMC Cancer. 2009;9:322.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Inagaki D, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Yamada T, et al. Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer. Anticancer Res. 2010;30:4127–30.PubMedGoogle Scholar
  48. 48.
    Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:3450–6.Google Scholar
  49. 49.
    Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:3113–9.Google Scholar
  50. 50.
    Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, et al. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer. 2010;10:139.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Schelter F, Halbgewachs B, Baumler P, Neu C, Gorlach A, Schrotzlmair F, et al. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha. Clin Exp Metastasis. 2011;28:91–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Gong Y, Scott E, Lu R, Xu Y, Oh WK, Yu Q. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One. 2013;8:e77366.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Rho SB, Chung BM, Lee JH. TIMP-1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF. J Cell Biochem. 2007;101:57–67.CrossRefPubMedGoogle Scholar
  54. 54.
    Cui H, Grosso S, Schelter F, Mari B, Kruger A. On the pro-metastatic stress response to cancer therapies: evidence for a positive co-operation between TIMP-1, HIF-1alpha, and MIR-210. Front Pharmacol. 2012;3:134.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Huang L, Cheng HC, Isom R, Chen CS, Levine RA, Pauli BU. Protein kinase cepsilon mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis. J Biol Chem. 2008;283:7616–27.CrossRefPubMedGoogle Scholar
  56. 56.
    Dubinett SM, Elashoff D, Meyerson M. Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture? J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3209–11.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ying-Hua Chang
    • 1
    • 2
  • Yi-Jen Chiu
    • 3
  • Hung-Chi Cheng
    • 4
  • Fang-Ju Liu
    • 3
  • Wu-Wei Lai
    • 5
  • Hsiao-Jen Chang
    • 3
  • Pao-Chi Liao
    • 1
    • 3
  1. 1.Institute of Biopharmaceutical Sciences, College of MedicineNational Cheng Kung UniversityTainanTaiwan
  2. 2.Department of Cell and Regenerative Biology, School of Medicine and Public HealthUniversity of WisconsinMadisonUSA
  3. 3.Department of Environmental and Occupational Health, College of MedicineNational Cheng Kung UniversityTainanTaiwan
  4. 4.Institute of Biochemistry, College of MedicineNational Cheng Kung UniversityTainanTaiwan
  5. 5.Department of SurgeryNational Cheng Kung University HospitalTainanTaiwan

Personalised recommendations